Patients with locally advanced or metastatic pancreatic adenocarcinoma not eligible for
infusional fluorouracil, irinotecan and oxaliplatin (FOLFIRINOX) (PPS 2 or
hyperbilirubinemia, among other causes) will be treated with mFLOX regimen (fluorouracil
bolus and oxaliplatin). The primary endpoint is to assess the objective response rate
according to RECIST criteria (version 1.1) and the secondary endpoints are time until
clinical or radiological progression, overall survival, toxicity profile.